Want full text access to this journal?
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign UpCirculation
• journal#1
Dhanunjaya R Lakkireddy, Mina K Chung, Rakesh Gopinathannair, Kristen K Patton, Ty J Gluckman, Mohit Turagam, Jim Cheung, Parin Patel, Jaun Sotomonte, Rachel Lampert, Janet K Han, Bharath Rajagopalan, Lee Eckhardt, Jose Joglar, Kristin Sandau, Brian Olshansky, Elaine Wan, Peter A Noseworthy, Miguel Leal, Elizabeth Kaufman, Alejandra Gutierrez, Joseph M Marine, Paul J Wang, Andrea M Russo
Covid-19 is a global pandemic that is wreaking havoc with the health and economy of much of human civilization. Electrophysiologists have been impacted personally and professionally by this global catastrophe. In this joint document from representatives of the HRS, ACC and AHA we identify the potential risks of exposure to patients, allied health care staff, industry representatives and hospital administrators. We describe the impact of COVID-19 on cardiac arrhythmias and methods of triage based on acuity and patient comorbidities...
March 31, 2020: Circulation
#2
Peter Marstrand, Larry Han, Sharlene M Day, Iacopo Olivotto, Euan A Ashley, Michelle Michels, Alexandre C Pereira, Samuel G Wittekind, Adam Helms, Sara Saberi, Daniel Jacoby, James S Ware, Steven D Colan, Christopher Semsarian, Jodie Ingles, Neal K Lakdawala, Carolyn Y Ho
Background: The terminology "end-stage" has been used to describe hypertrophic cardiomyopathy (HCM) with left ventricular systolic dysfunction (herein referred to as HCM-LVSD), defined when left ventricular ejection fraction (LVEF) <50% is present. The prognosis of HCM-LVSD has reportedly been poor, but due to its relative rarity, natural history remains incompletely characterized. Methods: Data from eleven high-volume HCM specialty centers comprising the international Sarcomeric Human Cardiomyopathy Registry (SHaRe) were used to describe the natural history of patients with HCM-LVSD...
March 31, 2020: Circulation
#3
Duk-Woo Park, Jung-Min Ahn, Hanbit Park, Sung-Cheol Yun, Do-Yoon Kang, Pil Hyung Lee, Young-Hak Kim, Do-Sun Lim, Seung-Woon Rha, Gyung-Min Park, Hyeon-Cheol Gwon, Hyo-Soo Kim, In-Ho Chae, Yangsoo Jang, Myung-Ho Jeong, Seung-Jea Tahk, Ki Bae Seung, Seung-Jung Park
No abstract text is available yet for this article.
March 30, 2020: Circulation
#4
EDITORIAL
Fernando Alfonso, Adnan Kastrati
No abstract text is available yet for this article.
March 30, 2020: Circulation
#5
Barrak Alahmad, Haitham Khraishah, Ahmed F Shakarchi, Mazen Albaghdadi, Sanjay Rajagopalan, Petros Koutrakis, Farouc Jaffer
No abstract text is available yet for this article.
March 30, 2020: Circulation
#6
Gregory G Schwartz, Ph Gabriel Steg, Michael Szarek, Vera A Bittner, Rafael Diaz, Shaun G Goodman, Yong-Un Kim, J Wouter Jukema, Robert Pordy, Matthew T Roe, Harvey D White, Deepak L Bhatt
Background: Patients with acute coronary syndrome (ACS) are at risk for peripheral artery disease (PAD) events and venous thromboembolism (VTE). Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors reduce lipoprotein(a) and low-density lipoprotein cholesterol (LDL-C) levels. Our objective was to ascertain whether PCSK9 inhibition reduces the risk of PAD events or VTE after ACS, and if such effects are related to levels of lipoprotein(a) or LDL-C. Methods: This was a prespecified analysis of the ODYSSEY OUTCOMES randomized clinical trial, which was conducted in 18 924 patients with recent ACS on intensive or maximum-tolerated statin treatment who were randomized to the PCSK9 inhibitor alirocumab or placebo...
March 29, 2020: Circulation
#7
John H Alexander, Daniel Wojdyla, Amit N Vora, Laine Thomas, Christopher B Granger, Shaun G Goodman, Ronald Aronson, Stephan Windecker, Roxana Mehran, Renato D Lopes
Background: In AUGUSTUS, patients with atrial fibrillation (AF) and a recent acute coronary syndrome (ACS) and/or those undergoing percutaneous coronary intervention (PCI) had less bleeding with apixaban than vitamin K antagonist (VKA) and with placebo than aspirin, however, the number of ischemic events was numerically higher with placebo. The aim of this analysis is to assess the tradeoff of risk (bleeding) and benefit (ischemic events) over time with apixaban versus VKA and aspirin versus placebo. Methods: In AUGUSTUS, 4614 patients with AF and recent ACS and/or PCI on a P2Y12 inhibitor were randomized to blinded aspirin or placebo and to open-label apixaban or VKA for 6 months...
March 29, 2020: Circulation
#8
Nicholas A Marston, Yared Gurmu, Giorgio E M Melloni, Marc Bonaca, Baris Gencer, Peter S Sever, Terje R Pedersen, Anthony C Keech, Carolina Roselli, Steven A Lubitz, Patrick T Ellinor, Michelle L O'Donoghue, Robert P Giugliano, Christian T Ruff, Marc S Sabatine
Background: The relationship between cholesterol levels and risk of venous thromboembolism (VTE) is uncertain. We set out to determine the effect of PCSK9 inhibition on the risk of VTE, explore potential mechanisms, and examine the efficacy in clinically and genetically defined risk subgroups. Methods: We performed a post-hoc analysis of the FOURIER trial testing whether evolocumab reduces the risk of VTE events (deep venous thrombosis or pulmonary embolism). Data from FOURIER and ODYSSEY OUTCOMES were then combined in a meta-analysis to assess class effect of PCSK9 inhibition on the risk of VTE...
March 29, 2020: Circulation
#9
Simon Yadgir, Catherine Owens Johnson, Victor Aboyans, Oladimeji M Adebayo, Rufus Adesoji Adedoyin, Mohsen Afarideh, Fares Alahdab, Alaa Alashi, Vahid Alipour, Jalal Arabloo, Samad Azari, Celine M Barthelemy, Catherine P Benziger, Adam E Berman, Ali Bijani, Juan J Carrero, Félix Carvalho, Ahmad Daryani, Andre R Durães, Alireza Esteghamati, Talha A Farid, Farshad Farzadfar, Eduarda Fernandes, Irina Filip, Mohamed M Gad, Samer Hamidi, Simon I Hay, Olayinka Stephen Ilesanmi, Seyed Sina Naghibi Irvani, Mikk Jürisson, Amir Kasaeian, Andre Pascal Kengne, Abdur Rahman Khan, Adnan Kisa, Sezer Kisa, Dhaval Kolte, Navid Manafi, Amir Manafi, George A Mensah, Erkin M Mirrakhimov, Yousef Mohammad, Ali H Mokdad, Ruxandra Irina Negoi, Huong Lan Thi Nguyen, Trang Huyen Nguyen, Molly R Nixon, Catherine M Otto, Shanti Patel, Thomas Pilgrim, Amir Radfar, David Laith Rawaf, Salman Rawaf, Wasiq Faraz Rawasia, Aziz Rezapour, Leonardo Roever, Anas M Saad, Seyedmohammad Saadatagah, Subramanian Senthilkumaran, Karen Sliwa, Berhe Etsay Tesfay, Bach Xuan Tran, Irfan Ullah, Muthiah Vaduganathan, Tommi Juhani Vasankari, Charles D A Wolfe, Naohiro Yonemoto, Gregory A Roth
Background: Non-rheumatic valvular heart diseases (NRVDs) are common; however, no studies have estimated their global or national burden. As part of the Global Burden of Disease (GBD) 2017 study, mortality, prevalence, and disability-adjusted life years (DALYs) for calcific aortic valve disease (CAVD), degenerative mitral valve disease (DMVD), and other NRVD were estimated for 195 countries and territories from 1990 to 2017. Methods: Vital registration data, epidemiological survey data, and administrative hospital data were used to estimate disease burden using the GBD modeling framework, which ensures comparability across locations...
March 29, 2020: Circulation
#10
Javed Butler, Kevin J Anstrom, Paul W Armstrong
No abstract text is available yet for this article.
March 28, 2020: Circulation
#11
Deepak L Bhatt, John W Eikelboom, Stuart J Connolly, Ph Gabriel Steg, Sonia S Anand, Subodh Verma, Kelley R H Branch, Jeffrey Probstfield, Jackie Bosch, Olga Shestakovska, Michael Szarek, Aldo Pietro Maggioni, Petr Widimský, Alvaro Avezum, Rafael Diaz, Basil S Lewis, Scott D Berkowitz, Keith A A Fox, Lars Ryden, Salim Yusuf
Background: Patients with established coronary artery disease (CAD) or peripheral artery disease (PAD) often have diabetes mellitus. These patients are at high risk of future vascular events. Methods: In a prespecified analysis of the COMPASS trial, we compared the effects of rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg daily) versus placebo plus aspirin in patients with diabetes versus without diabetes in preventing major vascular events. The primary efficacy endpoint was the composite of cardiovascular death, myocardial infarction (MI), or stroke...
March 28, 2020: Circulation
#12
Yaling Han, Hesong Zeng, Hong Jiang, Yuejin Yang, Zuyi Yuan, Xiang Cheng, Zhicheng Jing, Bin Liu, Jiyan Chen, Shaoping Nie, Jianhua Zhu, Fei Li, Changsheng Ma
No abstract text is available yet for this article.
March 27, 2020: Circulation
#13
Kaiming Wang, Mahmoud Gheblawi, Gavin Y Oudit
No abstract text is available yet for this article.
March 26, 2020: Circulation
#14
Orly Vardeny, Mohammad Madjid, Scott D Solomon
No abstract text is available yet for this article.
March 25, 2020: Circulation
#15
Giulio G Stefanini, Elena Azzolini, Gianluigi Condorelli
No abstract text is available yet for this article.
March 24, 2020: Circulation
#16
Le Ma, Gang Liu, Ming Ding, Geng Zong, Frank B Hu, Walter C Willett, Eric B Rimm, JoAnn E Manson, Qi Sun
No abstract text is available yet for this article.
March 23, 2020: Circulation
#17
Yanyan Xu, Haojie Jiang, Li Li, Fengwu Chen, Yunxia Liu, Meiyi Zhou, Ji Wang, Jingjing Jiang, Xiaoying Li, Xuemei Fan, Lin Zhang, Junfeng Zhang, Junqiang Qiu, Yi Wu, Chao Fang, Haipeng Sun, Junling Liu
Background: Branched-chain amino acids (BCAAs), essential nutrients including leucine, isoleucine and valine, serve as a resource for energy production and the regulator of important nutrient and metabolic signals. Recent studies have suggested that dysfunction of BCAA catabolism is associated with a risk of cardiovascular disease. Platelets play an important role in cardiovascular disease, but the functions of BCAA catabolism in platelets remain unknown. Methods: The activity of human platelets from healthy subjects before and after ingestion of BCAAs were measured...
March 23, 2020: Circulation
#18
Joseph A Hill, Darren K McGuire, James A de Lemos
No abstract text is available yet for this article.
March 21, 2020: Circulation
#19
Kevin J Clerkin, Justin A Fried, Jayant Raikhelkar, Gabriel Sayer, Jan M Griffin, Amirali Masoumi, Sneha S Jain, Daniel Burkhoff, Deepa Kumaraiah, LeRoy Rabbani, Allan Schwartz, Nir Uriel
No abstract text is available yet for this article.
March 21, 2020: Circulation
#20
François Potus, Michael W Pauciulo, Elina K Cook, Na Zhu, Alexander Hsieh, Carrie L Welch, Yufeng Shen, Lian Tian, Patricia Lima, Jeffrey Mewburn, Christine L D'Arsigny, Katie A Lutz, Anna W Coleman, Rachel Damico, Brooke Snetsinger, Ashley Y Martin, Paul M Hassoun, William C Nichols, Wendy K Chung, Michael J Rauh, Stephen L Archer
Background: Pulmonary arterial hypertension (PAH) is a lethal vasculopathy. Hereditary cases are associated with germline mutations in BMPR2 and 16 other genes. However, these mutations occur in under 25% of idiopathic PAH patients (IPAH) and are rare in PAH associated with connective tissue diseases (APAH). Preclinical studies suggest epigenetic dysregulation, including altered DNA methylation, promotes PAH. Somatic mutations of Tet-methylcytosine-dioxygenase-2 ( TET2 ), a key enzyme in DNA demethylation, occur in cardiovascular disease and are associated with clonal hematopoiesis, inflammation and adverse vascular remodeling...
March 20, 2020: Circulation
Fetching more papers... 
